Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03793582 · ClinicalTrials.gov registry record
Impact of OSA on Outcomes in Acute Coronary Syndrome
A clinical trial of OSA and ACS (Acute Coronary Syndrome), sponsored by MetroHealth Medical Center.
- Completed
- Registry status
- 128
- Enrollment target
- 1
- Study location
NCT03793582: Completed study of OSA and ACS (Acute Coronary Syndrome), sponsored by MetroHealth Medical Center.
NCT03793582 is a study of OSA and ACS (Acute Coronary Syndrome) that has completed, run by MetroHealth Medical Center. The registered enrollment target is 128 participants, below the 156-participant average among 14 other OSA trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03793582, a study of OSA and ACS (Acute Coronary Syndrome), has completed, sponsored by MetroHealth Medical Center.
- COMPLETED
- Registry status
- 128 participants
- Enrollment target
- 1
- Study location
Study Summary
Elucidating the effects of obstructive sleep apnea (OSA) on cardiovascular outcomes in acute coronary syndrome (ACS) is crucial in risk assessments and therapeutic recommendations for affected individuals. Although large epidemiological studies have reported an association between OSA and both coronary heart disease (CHD) and heart failure (HF), its effect on outcomes in ACS is still unclear. In contrast to previous theories attributing causation to OSA, recent studies have hypothesized a cardio protective role of OSA. Repetitive hypoxemic episodes noted in OSA may lead to myocardial ischemic preconditioning, possibly by increasing coronary collateral vessel recruitment, conferring protection from acute coronary events. We propose a prospective, observational, single center study in patients presenting with ACS, including ST segment elevation (STEMI), non-ST segment elevation (NSTEMI) and unstable angina who undergo coronary revascularization to determine the impact of OSA on clinical outcomes after ACS. Adult patients above age 18 years who present with myocardial infarction are eligible. Recruited patients will undergo an overnight sleep study using a level III portable diagnostic device before hospital discharge. The sleep tracings will be analyzed and audited by a certified sleep physician. The patients will be divided into 2 groups based on apnea-hypopnea index (AHI): OSA (AHI ≥ 15) and non-OSA (AHI \< 15) groups. The primary end points of this study were in-hospital, 30 day and 6 month major adverse cardiovascular events (MACE), defined as a composite endpoint of cardiovascular death, non-fatal MI, stroke and the need for unplanned repeat revascularization. Secondary endpoints include individual MACE outcomes of cardiovascular death, non-fatal MI, stroke, need for unplanned repeat revascularization, heart failure requiring hospitalization, and all-cause mortality.
Primary Outcome
Number of patients with major adverse cardiac events (MACE)
Conditions Studied
Interventions
- DIAGNOSTIC_TEST ApneaLink Type III portable sleep study
Study Locations (1)
Ohio
- MetroHealth Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2017-08-29 |
| Est. Completion | 2019-12-31 |
What the finished NCT03793582 record still lists
NCT03793582 is an observational study that tracks outcomes without assigning an intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 156-participant average among 14 other OSA trials with a reported enrollment target (18% lower).
The record links to 3 conditions, with OSA appearing as the primary indexed condition, and to 1 intervention - of which ApneaLink Type III portable sleep study is the first listed.
NCT03793582 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03793582 about?
NCT03793582 is a clinical study titled "Impact of OSA on Outcomes in Acute Coronary Syndrome". Elucidating the effects of obstructive sleep apnea (OSA) on cardiovascular outcomes in acute coronary syndrome (ACS) is crucial in risk assessments and therapeutic recommendations for affected individuals. Although large epidemiological studies have reported an association between OSA and both coron...
What is the current status of trial NCT03793582?
This trial is currently completed. The enrollment target is 128 participants. The study started on 2017-08-29. Estimated completion is 2019-12-31.
What conditions does trial NCT03793582 study?
This clinical trial studies the following conditions: OSA, ACS (Acute Coronary Syndrome), Major Adverse Cardiac Events.
What interventions are being tested in trial NCT03793582?
The interventions under investigation include: ApneaLink Type III portable sleep study (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03793582?
This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03793582 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OSA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03793582's enrollment target sits among peer trials
128 6th of 14 higher than 9 of 14 other OSA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other OSA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA
RECRUITING · Phase 1
-
Diagnosing Obstructive Sleep Apnea Using Electromyography of the Muscles of the Mouth
RECRUITING
-
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
RECRUITING · Phase 1
-
Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA
RECRUITING · NA
-
The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI